SEC Filing Summary: Form 8-K
Business Context and Reporting Period
This Form 8-K was filed by AspenBio Pharma, Inc. (not Riot Platforms, Inc.) on November 20, 2012. The report covers a specific corporate event occurring on the same date regarding the closing of a public offering.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial metric disclosed is the issuance of 1,946,000 shares of common stock.
Material Changes
The material change reported is the closing of a public offering of 1,946,000 shares of common stock. This event increases the company's outstanding share count and capital base, though the specific proceeds amount is not detailed in the text of this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the offering closure. The press release detailing the offering is filed as Exhibit 99.1.
Investor Verification Checklist
- Verify the total gross proceeds from the sale of 1,946,000 shares by reviewing Exhibit 99.1 (Press Release).
- Confirm the offering price per share to calculate total capital raised.
- Check subsequent filings for the impact of this share issuance on diluted earnings per share and total outstanding shares.
- Note the discrepancy between the requested company name (Riot Platforms) and the actual registrant (AspenBio Pharma).